6. INH—100 mg Tablets

7. Morphazinamide—500 mg. Tablets.

8. Prothionamide—125 mg Tablets.

9. Pyrazinamide—500 mg/750 mg. Tablets.

10. Rifampicin—150 mg./300 mg./450 mg. Capsules.

11. Terizidane.

12. Rifampicin—300 mg. + 200 mg.
450 mg. + INH 300 mg.
600 mg. 300 mg.

13. Sodium PAS—834 mg. + INH—25 mg.

14. Thiazetozon 150 mg. + INH 30 mg.

Each vial contains
Streptomycin Sulphate 1 gm. + Sodium methanesulfenate of INH—300 mg.

Shifting of TB drugs from category I to category II of price control order

149. DR. BAPU KALDATE: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government are aware of the move to shift certain potent and major TB drugs from category I to category II of Drugs Prices Control Order;

(b) whether it is a fact that as per the Policy decision, all anti-TB drugs have to be included under category I; and

(c) if so, on what basis such a move has been initiated and what is the *locus standi* of the Ministry in this regard?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) to (c) Anti-TB drugs identified by the Director General of Health Services for the National TB Control Programme were included in Category I of the Drugs Price Control Order, 1987 Government have recommended reclassification of Rifampicin from Category I to Category II, the criterion being the high technology involved in the manufacture of the drug thereby requiring incentives for production.

Budget provision for the purchase of medicine under National Health Programme

150. DR. BAPU KALDATE: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) what is the total budget provision for the purchase of medicines required for control of diseases under National Health Programme in 1988-89;

(b) what are the names of the drugs, based on which Government purchased medicines during 1987-88 for these programmes;

(c) whether Government have allocated separate budget for purchase of medicines for each disease;

(d) if so, the details of budget allocated for each during last three years, year-wise;

(e) what are the basis of selection of drugs for each disease and whether any exclusion or inclusion has been done during last two years; and

(f) if so, what are the names of drugs/medicines?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) to (f) The

information is being collected and will be laid on the Table of the Sabha

Non-inclusion of drugs for maternal and Child Health Programme under Price Control of the Drugs

151. SHRI V. NARAYANASAMY:
PROF. C. LAKSHMANNA:
SHRI RAM CHANDRA VIKAL:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Maternal and Child Health Programme is a National Programme and Iron, Folic Acid Tablets, Vitamin A solution are used under Proplyoxic Scheme; if so, what are the reasons for which Government did not recommend this programme and drugs used for this programme, for inclusion under price control;

(b) whether it is a fact that as per policy decision taken in 1986, all drugs needed for all National Health Programmes are to be covered under price control;

(c) if so, what are the reasons and factors under which Government deviated from the policy decision announced in December, 1986;

(d) whether there was any change in the policy;

(e) if so, the date when such a change was made;

(f) whether such a change has the approval of Cabinet; and

(g) if so, the date when the approval was obtained and what are the details of the changed policy?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) to (g) Government had recommended for inclusion under Category I of the Drugs Price Control Order, 1987, drugs identified for 8 National Health Programmes. Drugs for the Maternal and Child Health Programme, some of which are listed in Category-II, are being evaluated for Category-I price control recommendations to the Department of Chemicals and Petrochemicals. Policy decision regarding the Drugs Price Control Order is the responsibility of that Department.

Marketing of the STD Drugs

152. SHRI V. NARAYANASAMY:
SHRI RAM CHANDRA VIKAL:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to refer to the answer to Unstarred Question No. 1858 given on Rajya Sabha on 11th May, 1988 and state:

(a) what are the names of the drugs cleared for marketing for the treatment of STD;

(b) what is the strength and form under which each drug has been allowed for marketing for treatment of STD;

(c) what are the names of the drugs which have been classified as principal drugs for the treatment of STD;

(d) whether it is a fact that STD is covered under National Health Programme; and

(e) if so, whether Government have recommended this disease to be covered under category I?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) and (b) The names of drugs cleared for marketing of STD alongwith strength and form are given in the enclosed statement. (See below)

(c) to (e) STD is covered under the National Health Programmes. Drugs for this Programme are being evaluated for price control recommendations to the Department of Chemicals.